CF PHARMTECH (02652) spent approximately HK$370,500 to repurchase 10,500 shares on February 10th.
Chang Feng Pharmaceutical (02652) announced that on February 10, 2026, it spent approximately HKD 370,500 to repurchase 10,500 shares.
CF PHARMTECH (02652) announced that on February 10, 2026, it will spend approximately HK$370,500 to repurchase 10,500 shares.
Related Articles
Jiangsu Hengrui Pharmaceuticals (01276): Application for market approval of injection Rituximab accepted and included in priority review process.
CR ASIA (00831) announces profit growth is expected to increase by more than 40% annually for the 2025 fiscal year.
JINKE SERVICES (09666) spent HK$3.3741 million on February 10 to repurchase 38,830 shares.
Jiangsu Hengrui Pharmaceuticals (01276): Application for market approval of injection Rituximab accepted and included in priority review process.
CR ASIA (00831) announces profit growth is expected to increase by more than 40% annually for the 2025 fiscal year.
JINKE SERVICES (09666) spent HK$3.3741 million on February 10 to repurchase 38,830 shares.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
